drugset / Trial / NCT02653872

A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects

NCT02653872

Phase 1 Completed 15 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is a phase 1, non-randomized, fixed sequence, 3-period, drug-drug interaction study to assess the pharmacokinetics (PK) of AZD7986 in healthy subjects when administered alone and in combination with multiple doses of verapamil and itraconazole or diltiazem

Timeline

Start
2016-01-22
Primary completion
2016-04-13
Completion
2016-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Brensocatib Small molecule 25 mg Oral
Comparator Diltiazem Small molecule 360 mg
Comparator Itraconazole Small molecule 200 mg Oral
Comparator Verapamil Other / unclassified 240 mg Oral

Indications

No indication recorded.